Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 16, 2015 - Issue 7
Submit an article Journal homepage
508
Views
4
CrossRef citations to date
0
Altmetric
Letter to the Editor

Current lipid-modifying agents

Aris P AgouridisUniversity of Ioannina, Medical School, Department of Internal Medicine, 45110 Ioannina, Greece;Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free London Foundation Trust, Pond Street, London, NW3 2QG, UK+44 20 7830 2258; +44 20 7830 2235; [email protected]
(Honorary Clinical Research Fellow) ,
Theodosios D FilippatosUniversity of Ioannina, Medical School, Department of Internal Medicine, 45110 Ioannina, Greece
&
Niki KatsikiAristotle University of Thessaloniki, Hippokration Hospital, Second Propedeutic Department of Internal Medicine, Medical School, Thessaloniki, Greece
Pages 1117-1118 | Published online: 06 Apr 2015
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days
"Current lipid-modifying agents." Expert Opinion on Pharmacotherapy, 16(7), pp. 1117–1118

Declaration of interest

AP Agouridis is supported by a grant from the Hellenic Atherosclerosis Society. TD Filippatos has given talks and attended conferences sponsored by Bristol-Myers Squibb, Pfizer, Lilly, Abbott, Amgen, AstraZeneca, Novartis, Vianex, Teva and MSD. N Katsiki has given talks, attended conferences and participated in trials sponsored by Novartis, Novo Nordisk, MSD, Winmedica and AstraZeneca. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination.
Source: Springer Science and Business Media LLC

Linking provided by 
Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.